Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track INAB with free AI briefings, catalyst countdowns, and dilution alerts.

INAB · IN8BIO, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$14.2M Cash on Hand
11.1mo Cash Runway
Follow INAB by email Get an email when INAB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about INAB, unsubscribe in one click. Privacy

📣 What INAB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Allogeneic Gene-modified Gamma Delta T-cells Glioblastoma Phase 1/2 · NCT05664243 Active not recruiting
Autologous genetically modified gamma-delta T… Glioblastoma Phase 1/2 · NCT05664243 Active not recruiting
EAGD T-cell infusion (Expansion) Acute Myeloid Leukemia Phase 1 · NCT03533816 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INAB holds $14.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.8M/quarter from operations, an estimated runway of 11.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INAB files for a raise →

👥 Who Owns INAB

Insiders 82.3% Other 5%+ holders 9.8% Institutions (24 holders) 7.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
Aaron G.L. Fletcher
10% owner · +3.26M options
Insider 8,600,001 79.57% 2025-05-02
Leslie W. Kreis
10% owner · +3.26M options
Includes shares also reported by Aaron G.L. Fletcher, counted once
Insider 8,600,001 79.57% 2025-05-02
LYTTON LAURENCE W 5%+ holder (13G) 1,056,513 9.78% 2026-06-30
Stonepine Capital Management, LLC Institution (13G, 5%+) 1,007,990 9.33% 2025-12-19
Alyeska Investment Group, L.P. Institution (13G, 5%+) 966,381 8.94% 2025-12-31
Franklin Resources, Inc. Institution (13G, 5%+) 914,531 8.46% 2025-12-31
683 Capital Management, LLC Institution (13G, 5%+) 770,445 7.13% 2025-12-22
William Tai-Wei Ho
CEO, Director · +1.44M options
Insider 124,817 1.15% 2025-12-22
Peter C. Brandt
Director · +85,150 options
Insider 98,690 0.91% 2025-12-22
Alan S. Roemer
Director · +154,609 options
Insider 49,514 0.46% 2025-12-22
Patrick McCall
CHIEF FINANCIAL OFFICER · +494,742 options
Insider 9,482 0.09% 2025-12-22
Kate Rochlin
President and COO · +491,245 options
Insider 9,085 0.08% 2025-12-22

Share count 10,808,292 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full INAB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INAB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.